Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Target Price at $10.10

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have earned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $10.10.

A number of brokerages have weighed in on CRDF. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Noble Financial assumed coverage on Cardiff Oncology in a research note on Monday, January 5th. They issued an “outperform” rating and a $12.00 target price for the company. Wall Street Zen upgraded Cardiff Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Finally, Piper Sandler lowered their price target on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th.

Hedge Funds Weigh In On Cardiff Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jeppson Wealth Management LLC acquired a new position in shares of Cardiff Oncology in the 3rd quarter valued at $25,000. Brooklyn Investment Group acquired a new stake in shares of Cardiff Oncology during the 3rd quarter worth $26,000. Capital Advisors Wealth Management LLC purchased a new position in shares of Cardiff Oncology in the 4th quarter worth $30,000. Tamar Securities LLC purchased a new position in shares of Cardiff Oncology in the 4th quarter worth $32,000. Finally, R Squared Ltd acquired a new position in Cardiff Oncology in the fourth quarter valued at $36,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Price Performance

Cardiff Oncology stock opened at $1.58 on Friday. The stock has a market capitalization of $108.01 million, a P/E ratio of -2.29 and a beta of 1.42. Cardiff Oncology has a 12-month low of $1.48 and a 12-month high of $4.56. The firm’s 50-day moving average is $1.78 and its two-hundred day moving average is $2.18.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%. The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. As a group, analysts forecast that Cardiff Oncology will post -0.99 EPS for the current year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.